BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: To evaluate a relation between BRCA1/2 status and the Chemotherapy Response Score in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy and interval debulking surgery.
METHODS: Data were retrospectively collected on patients with unresectable disease undergoing three or four cycles of neoadjuvant chemotherapy and interval debulking surgery at the Gynecologic Oncology Unit of the Catholic University of the Sacred Heart from January 2016 to December 2020. All patients were assessed for BRCA1/2 somatic mutation at diagnosis. The omental specimens obtained at the interval surgery were evaluated according to Bohm's Chemotherapy Response Score System.
RESULTS: A total of 172 patients were included in the analysis, 69 (40%) patients were BRCA1/2 mutation carriers and 103 (60%) patients were wild type. In the wild-type group (BRCAwt), 73 (70.9%) patients had a Chemotherapy Response Score of 1 or 2 and 30 (29.1%) patients had a score of 3. In the BRCA1/2 carriers group (BRCAmut), 39 (56.5%) patients had a score of 1 or 2 and 30 (43.5%) patients had a score of 3. Among the BRCAwt group, those with a Chemotherapy Response Score of 3 had a prolonged median progression-free survival (22 vs 15 months, p=0.003). Among the BRCAmut carriers group, no differences were found (30 vs 27 months, p=0.55). No difference in overall survival was observed in either the BRCAmut carriers population (p=0.23) or the BRCAwt population (60 vs 44 months, p=0.06).
CONCLUSIONS: Patients with BRCA1/2mut seem to achieve a score of 1, 2 or 3 with the same frequency. In contrast, patients with BRCAwt seem to have a score of 1 or 2 more frequently than a score of 3. In patients with BRCA1/2mut, this score may not be an indicator of chemosensitivity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 32(2022), 5 vom: 03. Mai, Seite 639-645 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ergasti, Raffaella [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.05.2022 Date Revised 27.05.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/ijgc-2021-003116 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337775559 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337775559 | ||
| 003 | DE-627 | ||
| 005 | 20231225235158.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ijgc-2021-003116 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337775559 | ||
| 035 | |a (NLM)35246469 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ergasti, Raffaella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.05.2022 | ||
| 500 | |a Date Revised 27.05.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: To evaluate a relation between BRCA1/2 status and the Chemotherapy Response Score in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy and interval debulking surgery | ||
| 520 | |a METHODS: Data were retrospectively collected on patients with unresectable disease undergoing three or four cycles of neoadjuvant chemotherapy and interval debulking surgery at the Gynecologic Oncology Unit of the Catholic University of the Sacred Heart from January 2016 to December 2020. All patients were assessed for BRCA1/2 somatic mutation at diagnosis. The omental specimens obtained at the interval surgery were evaluated according to Bohm's Chemotherapy Response Score System | ||
| 520 | |a RESULTS: A total of 172 patients were included in the analysis, 69 (40%) patients were BRCA1/2 mutation carriers and 103 (60%) patients were wild type. In the wild-type group (BRCAwt), 73 (70.9%) patients had a Chemotherapy Response Score of 1 or 2 and 30 (29.1%) patients had a score of 3. In the BRCA1/2 carriers group (BRCAmut), 39 (56.5%) patients had a score of 1 or 2 and 30 (43.5%) patients had a score of 3. Among the BRCAwt group, those with a Chemotherapy Response Score of 3 had a prolonged median progression-free survival (22 vs 15 months, p=0.003). Among the BRCAmut carriers group, no differences were found (30 vs 27 months, p=0.55). No difference in overall survival was observed in either the BRCAmut carriers population (p=0.23) or the BRCAwt population (60 vs 44 months, p=0.06) | ||
| 520 | |a CONCLUSIONS: Patients with BRCA1/2mut seem to achieve a score of 1, 2 or 3 with the same frequency. In contrast, patients with BRCAwt seem to have a score of 1 or 2 more frequently than a score of 3. In patients with BRCA1/2mut, this score may not be an indicator of chemosensitivity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BRCA1 protein | |
| 650 | 4 | |a BRCA2 protein | |
| 650 | 4 | |a ovarian cancer | |
| 700 | 1 | |a Marchetti, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Tudisco, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Iervolino, Adelaide |e verfasserin |4 aut | |
| 700 | 1 | |a Naldini, Angelica |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Inzani, Frediano |e verfasserin |4 aut | |
| 700 | 1 | |a Scambia, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Fagotti, Anna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of gynecological cancer : official journal of the International Gynecological Cancer Society |d 1992 |g 32(2022), 5 vom: 03. Mai, Seite 639-645 |w (DE-627)NLM090676645 |x 1525-1438 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2022 |g number:5 |g day:03 |g month:05 |g pages:639-645 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ijgc-2021-003116 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2022 |e 5 |b 03 |c 05 |h 639-645 | ||